News
Public · Published
House bill aims to overhaul federal scheduling of drugs
Rep. Steve Cohen introduced a House bill that would move primary authority for scheduling controlled substances, including cannabis, from the Attorney General to the HHS Secretary, add five alphabetical schedules based on therapeutic value, and require at least three FDA public meetings on marijuana regulation.
Published:
Updated:
What happened
Rep. Steve Cohen introduced a House bill that would move primary authority for scheduling controlled substances, including cannabis, from the Attorney General to the HHS Secretary, add five alphabetical schedules based on therapeutic value, and require at least three FDA public meetings on marijuana regulation.
Confirmed
Global impact / market context
Scheduling decides how cannabis is regulated, which shapes the costs and legal limits for listed cannabis companies such as Village Farms, Trulieve and Curaleaf. Shifting authority toward health officials could change the evidence used, but the bill faces a long path before becoming law.
Analyst inference
Cannabis producers trade partly on expectations about federal rules. A health-focused scheduling process could lower regulatory risk over time, but without enactment the current restrictions, tax burdens and banking limits remain, so share moves tied to this news rest on expectations rather than realized change.
Analyst inference
What to watch
- Watch whether the bill advances beyond introduction, since a House bill needs committee review, votes in both chambers and presidential approval before it can change scheduling rules. Confirmed
- Watch the proposed text for how the HHS Secretary, Attorney General and ONDCP would share scheduling power, because agency roles determine how fast reviews proceed. Proposed
- Watch for the FDA public meetings on marijuana regulation, which could produce health evidence that influences future rescheduling decisions and the outlook for cannabis companies. Analyst inference